-
公开(公告)号：US20110280889A1
公开(公告)日：2011-11-17
申请号：US13130665
申请日：2009-11-24
IPC分类号： A61K38/17 , C12N15/85 , C12N15/861 , C12N15/867 , C12N5/10 , A61P35/00 , C07K7/08 , C07K17/02 , C07K19/00 , C07K14/725 , A61K39/395 , A61K35/14 , C12N5/0783 , C12N15/12
CPC分类号： C07K14/7051 , A61K35/17 , A61K38/1774 , C07K2319/40 , C12N15/85
摘要： The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.
摘要翻译： 本发明涉及针对肿瘤相关抗原的高亲和力T细胞受体（TCR），编码其的分离的核酸分子，表达所述TCR的T细胞和用于治疗涉及恶性疾病的药物组合物 表达所述肿瘤相关抗原的细胞。
-
公开(公告)号：US08697854B2
公开(公告)日：2014-04-15
申请号：US13130665
申请日：2009-11-24
IPC分类号： C07K14/725 , C12N15/12
CPC分类号： C07K14/7051 , A61K35/17 , A61K38/1774 , C07K2319/40 , C12N15/85
摘要： The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.
摘要翻译： 本发明涉及针对肿瘤相关抗原的高亲和力T细胞受体（TCR），编码其的分离的核酸分子，表达所述TCR的T细胞和用于治疗涉及恶性疾病的药物组合物 表达所述肿瘤相关抗原的细胞。
-
3.发明申请REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF 有权ALLO-限制性肽特异性T细胞受体序列的替代物及其用途公开(公告)号：US20120128704A1
公开(公告)日：2012-05-24
申请号：US13148653
申请日：2010-02-09
IPC分类号： A61K31/7088 , C07K7/08 , C07K7/06 , A61P35/00 , C07K19/00 , A61K35/26 , A61P37/04 , C12N15/12 , C07K14/725
CPC分类号： C07K14/7051 , C07K14/70503
摘要： The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.
摘要翻译： 本发明涉及包含编码高亲合力，同种异体限制性TCR的核酸序列的成套工具或组合物，其中TCR独立地针对酪氨酸酶抗原，黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物，所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外，本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子，由此编码的TCR和表达所述TCR的T细胞。 此外，本发明公开了一种载体，细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。
-
4.发明授权Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof 有权同种异体限制性肽特异性T细胞受体序列的汇编及其用途公开(公告)号：US09409969B2
公开(公告)日：2016-08-09
申请号：US13148653
申请日：2010-02-09
IPC分类号： C07H21/04 , C07K14/705
CPC分类号： C07K14/7051 , C07K14/70503
摘要： The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.
摘要翻译： 本发明涉及包含编码高亲合力，同种异体限制性TCR的核酸序列的成套工具或组合物，其中TCR独立地针对酪氨酸酶抗原，黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物，所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外，本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子，由此编码的TCR和表达所述TCR的T细胞。 此外，本发明公开了一种载体，细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。
-
公开(公告)号：US08486694B2
公开(公告)日：2013-07-16
申请号：US11990054
申请日：2006-08-04
IPC分类号： C12N5/10
CPC分类号： C07K14/705 , A61K2039/5154 , A61K2039/5156 , C12N5/0636 , C12N5/0639 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
摘要翻译： 本发明涉及产生抗原特异性T细胞的方法。 此外，本发明涉及抗原特异性T细胞，分离的转基因TCR，含有它们的药物组合物及其在过继性细胞治疗中的用途。 本发明特别涉及共表达同种异体MHC分子和抗原的细胞用于从非选择的同种异体T细胞库中诱导肽特异性T细胞的用途。
-
公开(公告)号：US20100189728A1
公开(公告)日：2010-07-29
申请号：US11990054
申请日：2006-08-04
CPC分类号： C07K14/705 , A61K2039/5154 , A61K2039/5156 , C12N5/0636 , C12N5/0639 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
摘要翻译： 本发明涉及产生抗原特异性T细胞的方法。 此外，本发明涉及抗原特异性T细胞，分离的转基因TCR，含有它们的药物组合物及其在过继细胞治疗中的用途。 本发明特别涉及共表达同种异体MHC分子和抗原的细胞用于从非选择的同种异体T细胞库中诱导肽特异性T细胞的用途。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.042 秒)
